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Ischemia–reperfusionMitochondria are one of themajor sources of reactive oxygen species (ROS) in the cell.When exceeding the capac-
ity of antioxidantmechanisms, ROS productionmay lead to different pathologies, such as ischemia–reperfusion in-
jury, neurodegeneration, anemia and ageing. As a consequence of the endosymbiotic origin of mitochondria,
eukaryotic cells have developed different transport mechanisms that coordinate mitochondrial function with
other cellular compartments. Four mitochondrial ATP-binding cassette (ABC) transporters have been described
to date in mammals: ABCB6, ABCB8, ABCB7 and ABCB10. ABCB10 is located in the inner mitochondrial membrane
forming homodimers, with the ATP binding domain facing the mitochondrial matrix. ABCB10 expression is highly
induced during erythroid differentiation and its overexpression increases hemoglobin synthesis in erythroid cells.
However, ABCB10 is also expressed in nonerythroid tissues, suggesting a role not directly related to hemoglobin
synthesis. Recent evidence points toward ABCB10 as an important player in the protection from oxidative stress
in mammals. In this regard, ABCB10 is required for normal erythropoiesis and cardiac recovery after ischemia–
reperfusion, processes intimately related to mitochondrial ROS generation. Here, we review the current knowl-
edge on mitochondrial ABC transporters and ABCB10 and discuss the potential mechanisms by which ABCB10
and its transport activity may regulate oxidative stress. We discuss ABCB10 as a potential therapeutic target
for diseases in which increased mitochondrial ROS production and oxidative stress play a major role.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Mitochondrial function is associated with reactive oxygen species
(ROS) generation. Different antioxidant enzymes (i.e. superoxide
dismutase 2, glutathione peroxidases, peroxiredoxin, thioredoxin re-
ductase, etc.) are located in the mitochondria where they maintain
ROS below toxic levels. In addition, ROS generation inside the mito-
chondria in the form of hydrogen peroxide can diffuse to the cytosol
and damage other subcellular compartments. Consistent with this,
overexpression of catalase targeted inside the mitochondrial matrix
was demonstrated to have protective effects in the entire cell [20].
In contrast, less is known about the molecular mechanisms allowing
an integrated and coordinated antioxidant response of the mitochon-
dria with the rest of the cell under conditions of increased oxidative
stress.
As a consequence of the endosymbiotic origin of mitochondria,
eukaryotic cells have developed different transport mechanisms in
order to coordinate mitochondrial function with other cellular com-
partments. Therefore, it is expected that mitochondrial importers
and exporters will be essential to coordinate, integrate and maintain arch Center, Boston University
USA. Tel.: +1 617 230 8570;
rights reserved.general antioxidant response. Recent data unravel novel mechanisms
involved in protection from oxidative stress, as they demonstrate
that the mitochondrial ATP binding cassette transporter ABCB10 is
required for an efﬁcient general antioxidant response in vivo [38,53].
ABCB10 was originally identiﬁed as ABC-me (ATP binding cassette-
mitochondrial erythroid) in mouse and M-ABC2 in humans [76,88].
ABCB10 is the closest mammalian ortholog to yeast MDL1 and to
Caenorhabditis elegans haf-3. ABCB10 is located in the inner mitochon-
drialmembrane, forminghomodimers, and its overexpression increases
hemoglobin synthesis [29,76]. ABCB10 expression in nonerythroid tis-
sues suggested a role not directly related to hemoglobin synthesis
[53,76]. Recent ABCB10 and MDL1 studies suggest that mitochondrial
export (of yet unidentiﬁed molecules) can constitute a novel pathway
to protect from oxidative stress in different cell types. In this review,
we will discuss the current knowledge on ABCB10 in the context of
mitochondrial ABC transporters of its subfamily.
2. Structure–function of ABC proteins and ABCB10
2.1. General features of ABC transporters
Although their functions are versatile, ABC transporters share
conserved structures. Most of the ﬁndings discussed in this section
have been described in other, non-mitochondrial, ABC proteins.
Given that ABC proteins have highly conserved domains, we expect
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porters can be formed by diverse numbers of polypeptide chains
(from 1 to 5). However, these polypeptide chains always fold to form
2 trans-membrane domains (TMD), which span the biological mem-
brane multiple times via α-helices and recognize the substrate/s, and
2 nucleotide binding domains (NBD), which bind and hydrolyze ATP
to provide energy for the substrate transport [33]. ABCB10, as in the
case of different ABC transporters, is formed by 2 polypeptide chains
(2 hemitransporters or monomers), each of them harboring a TMD
and a NBD (Fig. 1A and C) [29].While no reports on the crystal structure
of human mitochondrial ABC proteins have been published so far,
different mutagenesis studies, the characterization of their domains
and crystallographic studies of other ABC proteins provide important
insights on how ABCB10 might be functioning:
2.1.1. Transmembrane domain (TMD)
It is a relatively variable domain and this variability determines
ABC transporters speciﬁcity to their substrates. For example, the
multidrug resistance ABC transporter (MDR1/ABCB1) exports che-
motherapeutic drugs through the plasma membrane [11]. The trans-
porter associated with antigen presentation (TAP or ABCB2/ABCB3
heterodimer) transports antigenic peptides across the ER membrane
to assemble the MHC complex for the immune response [62], and the
cystic ﬁbrosis transmembrane conductance regulator (CFTR or ABCC7)
channels chloride and other anions out of epithelial cells [71]. In any
speciﬁc ABC transporter, the variability in single amino-acids of the
TMD determines the molecules transported and the throughput for
each one of them. For example, previous studies have shown that single
amino acid mutations in TMD alter CFTR/ABCC7 anion selectivity,
changing its preference for the different anions (Br−, Cl−, I−, and F−)
[3]. In addition, similar alterations in the TMD of ABCB1 change
substrate speciﬁcity [79] and inhibit drug resistance activity [81]. It
will be of interest to test whether speciﬁc mutations in the TMD of
ABCB10 can also change their substrate speciﬁcity and lead to different
physiological consequences.
2.1.2. NBD (nucleotide binding domain)
In contrast to TMD, the NBD contains highly conserved residues in
different ABC transporters, which form 3 characteristic motifs (in
both mitochondrial and non-mitochondrial): the Walker A, the Walk-
er B and the C-loop motifs (Fig. 1C). This is mainly due to the fact that
these residues bind and catalyze ATP hydrolysis to provide energy for
transport. Most of the functional characterizations of the NBD were
performed in non-mitochondrial ABC proteins and are summarized
in this section. Given this high degree of conservation, we expect
some similarities in the structure–function relation in ABCB10. The
most conserved residues in the 3 motifs are the following: theWalker
A motif is constituted by GXXGXGKS/T (where X is any amino acid),
the Walker B motif by HHHHD (H is any hydrophobic amino acid)
and the C-loop motif by LSGGQ. These 3 motifs were also identiﬁed
in ABCB10 (Fig. 1C) [76]. During a typical ABC-mediated transport
process (as described in the crystal structure of a non-mitochondrial
ABC protein, MalK, the ATPase subunit of the maltose ABC transporter
from Escherichia coli), two ATP molecules are buried between the two
monomers of the ABC transporter. Each ATP is positioned between
the Walker A motif of one monomer and the C-loop motif of the
other one. In this way, two NBDs form a dimeric sandwich with a
head to tail orientation [13]. The lysine residue in the Walker A
motif (Fig. 1C) is conserved for hydrogen bond interaction with the
β and γ phosphates of ATP and stabilization of the hydrolysis transi-
tion state during ATP hydrolysis [21]. A mutation of this residue re-
sults in almost complete loss of ATPase activity [61], which is due to
impaired ATP binding by the NBD [48]. The conserved glutamate res-
idue immediately following the Walker B motif is believed to be the
catalytic base for ATP hydrolysis (Fig. 1C). This negatively-charged
residue polarizes a nearby water molecule to attack the γ phosphate,which releases free energy. This is conﬁrmed by the ﬁnding that the
mutation in the glutamate residue does not affect the binding of
ATP by NBD but signiﬁcantly reduces ATP hydrolysis [60,83]. The
C-loop motif binds to ATP via the interaction of the serine and glycine
residues with the γ phosphate. Mutation of these residues of the
C-loop decreased ATP hydrolysis in CFTR (ABCC7), MDR1 (ABCB1)
and TAP (ABCB2/ABCB3 heterodimer) [14,57,78]. With the stable as-
sociation of ATP with the NBD maintained by the above conserved
residues and domains, one cycle of ATP hydrolysis proceeds, produc-
ing the free energy required for substrate transport. One cycle is con-
stituted by ATP hydrolysis, release of Pi and replacement of ADP with
new ATP [34]. Although it is still not clear how ATP hydrolysis is relat-
ed to substrate transport, a model suggests that the ATP hydrolysis at
the catalytic site of NBD leads to alteration in the backbone conforma-
tion of the LSGGQ sequence constituting the C-loop motif. This alter-
ation is propagated upstream to change the conformation of the
substrate-bound TMD, by rotating the variable NBD helical domain
that is close to the ATP binding pocket [42]. In this way, the substrate
is released from TMD and is transported across the biological mem-
branes. One could expect similar mechanisms in ABCB10. In addition,
mutations in any of the conserved NBD residues in ABCB10 are also
expected to abrogate its function. However, this needs to be con-
ﬁrmed by crystallographic and mutagenesis studies on ABCB10.
2.2. Structure–function of mitochondrial ABC transporters and ABCB10
ABCB10 is expected to show a similar structure–function relation-
ship as described above for ABC proteins. As an example, ABCB10
(with an open reading frame of 715 amino acids) has an ~400 amino
acid hydrophobic sequence that is believed to be the TMD and spans
the mitochondrial inner-membrane six times (Fig. 1A and C). After
the TMD, there are ~240 amino acids that constitute the NBD, which
contains the Walker A motif (GPSGSGKST), the C-loop motif (LSGGQ),
and theWalker Bmotif (LLLDE) (Fig. 1C). The NBD of ABCB10 is located
at the mitochondrial matrix, suggesting that ABCB10 might transport
substrates out of mitochondria through the mitochondrial inner-
membrane [76]. In contrast to other ABCnon-mitochondrial transporters,
ABCB10 has a long mitochondrial targeting sequence (105 amino acids)
that localizes ABCB10 into the mitochondrial inner-membrane (Fig. 1A).
Removal of these 105 amino acids targets ABCB10 to the endoplasmic re-
ticulum [29]. On the other hand, the ﬁrst 135 aa of ABCB10 can target
any membrane protein to the mitochondria [59]. Of the ﬁrst 105
amino-acids, the hydrophobic middle third (aa 36–70) is essential for
the mitochondrial targeting, whereas 1–35 and 71–105 aa are required
for proper mitochondrial import and insertion of ABCB10 in the inner
membrane (but not for mitochondrial targeting) [29]. After trafﬁcking
into the mitochondrial inner-membrane, the leading sequence is then
cleaved by enzymes inside the mitochondrial matrix [29]. This long
pre-sequence might have been incorporated during endosymbiosis
of the α-proteobacteria Rickettsia prowazekii (which is the probable
ancestor of mitochondria [4]), in order to avoid mistargeting of mito-
chondrial ABC transporters to other cellular compartments or mem-
branes (i.e. endoplasmic reticulum). Of note, there is no conservation
of ABCB10mitochondrial targeting sequence in the closest R. prowazekii
ortholog, demonstrating that this long sequence is an acquired feature
during or after endosymbiosis (ABCB10 identity starts at mouse
amino acid 181, which corresponds to amino acid 75 of R. prowazekii
Multidrug resistance protein). This feature was most likely acquired
when Rickettsia ABCB10 ortholog was transferred to the host cell nu-
clear DNA to become ABCB10.
ABCB10 forms a homodimer by combining two hemi-transporters
[29], as those found in other ABC transporters [84]. The residues re-
sponsible for ABCB10 dimerization have not been indentiﬁed [29].
How this homodimerization contributes to ABCB10 transport activity
is unknown. No ABCB10 structure–function studies (apart from the
mitochondrial targeting studies discussed) have been performed yet.
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Fig. 1. ABCB10 topology in the inner mitochondrial membrane and its functional domains. A) Cartoon representing ABCB10 topology in the inner mitochondrial membrane. ABCB10
nucleotide binding domain NBD is facing the mitochondrial matrix and 6 transmembrane domains span the inner mitochondrial membrane. ABCB10 forms homodimers and not
heterodimers. The location of the NBD, in the C-terminal portion of the protein, suggests that ABCB10 is exporting its substrate/s to the inner membrane space (IMS). The
N-terminal part of the protein contains a long mitochondrial pre-targeting sequence cleaved after insertion. Fluorescence microscope images of a mouse NIH-3T3 ﬁbroblast
expressing ABCB10-GFP (green) and stained with the mitochondrial membrane potential sensitive probe TMRE (red). Merged images show perfect co-localization of ABCB10-
GFP with TMRE, demonstrating that ABCB10-GFP targets to mitochondria. B) ABCB10 expression in different mouse tissues measured by Northern blot. Liver, heart, brain and
kidney show ABCB10 expression (highest levels in liver, kidney and heart). Differentiation of mouse erythroleukemia cells (MEL) is associated with GATA-1 activation (master tran-
scription factor regulating terminal eythroid differentiation and hemoglobin synthesis) and a large increase in ABCB10 expression measured by Northern blot. This ﬁgure was
adapted from Ref. [76], Shirihai et al. (2000) EMBO Journal. C) Alignment of human ABCB10 (NP_036221) and human ABCB1/MDR1 (NP_000918.2) amino-acidic sequences
using Blast P (37% identity covering a 78% of ABCB10 sequence). The transmembrane-TM- and nucleotide binding-NBD-domains are in light green and grey respectively. The
Walker A, B and C-loop motifs are highlighted within the NBD in different colors. Residues conserved in ABCB10 that were mutated in functional studies of ABCB1 or other ABC
proteins are marked with asterisks.
1947M. Liesa et al. / Biochimica et Biophysica Acta 1823 (2012) 1945–1957In addition, no ABCB10mutants have been described yet in humans and
it is unknown whether ABCB10 mutations are associated with patho-
logical states in humans. However, studies performed on other mito-
chondrial ABC transporters and the study of their structure–function
relationship may give some hints about ABCB10 transport activity. The
yeast protein ATM1 (ATP binding cassette Transporter Mitochondria
1; see Section 4.2 for a detailed description) has an N-terminal mito-
chondrial matrix-targeting signal and is localized in the mitochondrial
inner-membrane, with a C-terminal NBD facing the matrix [51]. In
a similar manner to other non-mitochondrial ABC transporters, the
conserved lysine residue in Walker A motif of ATM1 is responsible for
the ATP binding by NBD and the homodimerization of the two hemi-
transporters. The mutation of the NBD lysine to methionine causes
complete loss of ATM1 function [18]. ABCB7 is a mammalian ortholog
of yeast ATM1 (see Section 4.2). Mutations in ABCB7 are related to a
disease called X-linked sideroblastic anemia with ataxia (XLSA/A) in
humans. The heritage family study shows that the amino acid change
of E433K at the C-terminal of the sixth TMD [9,70] or V411L at thebeginning of the sixth TMD in ABCB7 is sufﬁcient to cause XLSA/A
[56]. These mutations in the TMD would suggest an alteration in the
substrate binding, speciﬁcity or transport efﬁciency of ABCB7 as a
cause for this disease. On the other hand, there are no reports describing
any XLSA/A patients harboring mutations in the conserved residues
of the Walker A motif, the Walker B motif or the C-loop motif of the
NBD. This lack ofmutations could be related to a vital role of this protein
in humans and to the likely possibility that mutations in these domains
would completely abrogate ABCB7 function. One could expect similar
patterns for ABCB10.
The potential substrates described so far for ABCB6 (another mito-
chondrial ABC transporter related toABCB7, see Section4) are porphyrins,
including heme, coproporphyrinogen III, and protoporphoryrinogen IX
[47]. These molecules harbor anionic carboxylate side chains and tetra-
pyrrole moieties, which could be speciﬁcally recognized and bound
by TMD of ABCB6. It would be of high interest to ﬁnd out whether
ABCB10 has a similar domain in order to know if it can transport similar
molecules, given that both ABCB6 and ABCB10 are involved in heme
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ABCB6 might transport other molecules into the mitochondria (or
other compartments), as ABCB6 deletion does not cause any defects in
erythropoeisis in humans (see Section 4) [32].
MDL1 is another mitochondrial ABC transporter in yeast [23] and
has a relatively high degree of homology to ABCB10 compared to
the rest of mitochondrial ABC transporters (43% identity, covering
78% of the aminoacidic sequence, see Sections 2 and 4) (Fig. 4). Sim-
ilarly, its TMD spans the mitochondrial inner-membrane six times
and its NBD is at the C-terminal residing in the mitochondrial matrix.
In Saccharomyces cerevisiae, peptides harboring 6 to 20 amino acids
(as a result of protein digestion products by m-AAA protease in the
mitochondrial matrix) are exported by MDL1 [87]. Given that MDL1
has a high degree of homology to ABCB10, one may hypothesize
that small peptides may also be the substrates of ABCB10. Thus, it
would be interesting to study whether these peptides could bind by
the uncharacterized substrate binding site in the TMD of ABCB10. In
addition, the glutamate immediately after the Walker B motif in
MDL1 NBD is the catalytic site for ATP hydrolysis, but this residue is
dispensable for ATP binding (consistent with other ABC proteins)
[35]. Moreover, mutations of other highly conserved residues, such
as glycine in the Walker A motif, aspartate in the Walker B motif
and serine in the C-loop motif decreases the release of peptides by
MDL1 into the cytoplasm [87]. These data conﬁrm that other mito-
chondrial ABC proteins have conserved structure–function character-
istics present in non-mitochondrial ABC proteins, despite being in
membranes with different phospholipid composition.
3. The role of ABCB10 (ABC-me/M-ABC2/mABC2) in protecting
from oxidative stress
ABCB10 was identiﬁed as ABC-me in mouse and M-ABC2 in
humans [76,88]. These different nomenclatures can generate some
confusion. Therefore, it is important to clarify that ABCB10, ABC-me,
M-ABC2, MTABC2, m-ABC2 and mABC2 are different names for the
same protein. This protein is different from ABCB8/mABC1/M-ABC1.
ABCB10 is the closest mammalian ortholog to yeast MDL1 (multidrug
resistance like 1 protein, 43% identity, covering 78% of the sequence)
and to C. elegans haf-3 (44% identity, covering 79% of the sequence).
Several studies have shown the importance of MDL1 function in
yeast physiology. On the other hand, to our knowledge, no studies
have shown in detail the precise function of haf-3 in C. elegans. How-
ever, one study describes that repression of haf-3 by siRNA or homo-
zygous deletion, does not activate the mitochondrial unfolded protein
response [31]. Determining haf-3 function and its substrates in
C. elegans may provide valuable information for the understanding
of ABCB10 function in mammals. On the other hand, the precise func-
tion of haf-3 homolog, haf-1, was described in the same study and
shares important similarities with ABCB10 yeast ortholog MDL1 [31].
Therefore, haf-1 function will be discussed in this review, as its descrip-
tionmight provide valuable information in order to understandABCB10
function, despite not being the closest ABCB10 C. elegans ortholog
(ABCB10 shares a 40% of identity with haf-1, covering 77% of its se-
quence). This similarity is lowerwhen compared to haf-3 but still signif-
icant (see above).
3.1. Function of ABCB10 orthologs in yeast, fungi and Caenorhabditis elegans
MDL1 and MDL2 were cloned using a gene mapping strategy in
yeast [23]. To our knowledge, the precise function of MDL2 is still
unknown; but its deletion impaired respiratory cell growth in yeast,
suggesting that it is required for basal mitochondrial function [87].
In contrast, MDL1 deletion did not impair growth under non-
fermentable carbon sources, showing that it is not required to maintain
mitochondrial function in the resting state [87]. MDL1 (but not MDL2)
exports peptides in isolated mitochondria preparations (cell-freesystems) from the matrix to the inter-membrane space. More speciﬁ-
cally, these peptides were digestion products of the matrix AAA prote-
ase (m-AAA mitochondrial protease), which is involved in protein
quality control [87]. This study provided the ﬁrst in vitro evidence of
the physiological role of MDL1.
One can hypothesize that the observed peptide export activity
may help preventing mitochondrial dysfunction induced by an abnor-
mal and sudden accumulation of peptides caused by increased dam-
age and turnover (i.e. increased ROS generation or mitochondrial
oxidative stress). This accumulation could potentially generate higher
order structures (protein aggregates) and irreversibly damage mito-
chondria, abrogating their ability to cope with the stress (i.e. such as
β-amyloid peptide accumulation in Alzheimer disease). Furthermore,
the formation of these aggregates could be stimulated and/or catalyzed
by reactive oxygen species, generating a vicious cycle (aggregates cause
dysfunction; mitochondrial dysfunction increases ROS, which promote
the formation of more aggregates). Indeed, deletion of Lon protease
located in the mitochondrial matrix causes the likely accumulation of
protein aggregates, which are associated with mitochondrial dysfunc-
tion and ROS generation [10]. Thus, accumulation of certain peptides
increased by stress conditions and exacerbated by MDL1 deletion
(i.e. high ROS) could cause a similar phenotype to Lon activity abro-
gation (despite the difference that lack of Lon activity would cause
the accumulation of misfolded proteins, and lack of MDL-1 accumu-
lation of peptides).
Another possibility is that these peptides exported by MDL1 were
not causing or facilitating the damage per se, but that they would
harbor a signal in order to communicate the mitochondria status to
the rest of the cell. This signal could be essential to activate cellular
antioxidant responses or mitochondrial quality control mechanisms
[7]. This would impede the recruitment of quality control mecha-
nisms when required and cause the accumulation of dysfunctional
mitochondria. Indeed, studies performed in C. elegans support this
hypothesis. Haf-1 deletion (MDL1 ortholog in C. elegans) caused an ac-
cumulation of peptides inside the mitochondrial matrix, which ham-
pered the activation of the transcription factor ZC376.7 and abrogated
a proper mitochondrial unfolded protein response [31]. As a result,
Haf-1 deletion caused mild mitochondrial dysfunction (measured as
decreased oxygen consumption in worms) under basal conditions,
which was exacerbated by exposing Haf-1-null worms to high temper-
ature (30 °C, which hampers protein folding in mitochondria) [31].
However, it is unknown whether potential protein aggregates consti-
tuted byHaf-1 substrates also contributed tomitochondrial dysfunction
or whether decreased mitochondrial respiration was only caused by
the lack of activation of quality control mechanisms.
These ﬁndings in yeast and C. elegans strongly suggest that MDL1/
haf-1 export activity might play a role in mitochondrial stress response,
but that it is not essential for viability under basal conditions. In this
regard, MDL1 over-expression was shown to prevent the abnormally
increased mitochondrial oxidative stress caused by ATM1 deletion
through an unknown mechanism [17]. Consistent with this, a study
characterizing the pathogenic fungus Paracoccidioides brasiliensis also
supports the hypothesis that MDL1 is important to copewith situations
of increased stress. This study shows that ABCB10 ortholog Pfr1 ismark-
edly increased under stress conditions. Pfr1 expression was increased
by treatmentwith ﬂuconazole (a fungicide), which damages the fungus
and their mitochondria by inhibiting the cytochrome P450 enzyme in-
volved in the synthesis of ergosterol [30].
3.2. ABCB10 (ABC-me)
As discussed in previous sections, one would expect that ABCB10
could play a role in peptide export and active protection from increased
oxidative stress, as it is the mitochondrial ABC transporter closer to
MDL1 in mammals [30,76,88,89]. In contrast, ABCB7, ABCB6 and ATM1
would be the mitochondrial ABC proteins involved in heme and iron
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ABCB10 (see Section 4) [30,88,89].
Despite these phylogenic features, different studies demonstrate
that ABCB10, like ATM1 and ABCB7, also plays an important role in
heme and iron metabolism [16,76]. A hypothesis that could reconcile
both predictions would state that ABCB10 activity confers a speciﬁc
antioxidant function (not present in lower eukaryotes or prokaryotes)
required to protect from oxidative damage speciﬁcally associated with
mammalian heme metabolism.
This hypothesis suggests that ABCB10 would be a version of MDL1
tuned to protect mitochondria from the oxidative challenges speciﬁ-
cally occurring in multi-cellular eukaryotic organisms (i.e. hemoglobin
synthesis). The mechanism for this protection could involve peptide
export and/or other molecules speciﬁcally regulating antioxidant func-
tion and/or avoiding mitochondrial oxidative damage. In this regard,
tissues with higher susceptibility to oxidative damage show ABCB10
expression [76,88]. Heart and hematopoetic tissues show high levels
of ABCB10 expression in mice (hematopoetic tissues with the highest
levels) [76]. These tissues handle two of the most challenging (physio-
logical and pathophysiological) processes dealing with increased mito-
chondrial oxidative stress: erythropoiesis (hemoglobin synthesis) and
cardiac ischemia reperfusion. Furthermore, liver and brain also show
considerable levels of ABCB10 expression. In both tissues, mitochon-
drial oxidative stress plays a major role in the pathogenic conse-
quences of ischemia–reperfusion (as in the heart). In this regard, we
expect that ABCB10 will play a protective role from oxidative stress in
these tissues too.
3.2.1. ABCB10 in erythropoiesis and heme metabolism
ABCB10 (ABC-me) was identiﬁed in mRNA subtractive analysis of
transcripts that are induced during erythroid differentiation by the
activation of the transcription factor GATA1 (a master regulator of
terminal erythroid differentiation) [76]. ABCB10 was identiﬁed as a
mitochondrial transporter and was localized in the inner membrane
(Fig. 1A). ABCB10 nucleotide binding domain (NBD) is facing the mi-
tochondrial matrix, suggesting that ABCB10 could export molecules
out of the mitochondria (Fig. 1A). However, some eukaryotic ABC
proteins showing the same topology (NBD oriented to the matrix)
have been shown to act as importers. Thus, ABCB10 location and the
possibility of harboring export activity made it an attractive candidate
for the missing mitochondrial exporters of amino-levulinic acid (ALA)
or heme, involved in heme/hemoglobin synthesis [76]. This hypothe-
sis was further supported by 3 different results:
1) The increase in hemoglobin levels and synthesis rates triggered
by ABCB10 overexpression in erythroid cells, without affecting differ-
entiation (Fig. 2B). 2) The increase in ABCB10 expression induced by
addition of exogenous amino-levulinic acid (ALA), which increases
heme synthesis (by-passing mitochondrial amino-levulinic acid syn-
thesis and export). 3) The decrease in ABCB10 expression by exoge-
nously added physiological heme levels (the ﬁnal product exported
by the mitochondria) [76]. These results (2 and 3) suggested that
ABCB10 could be involved in heme export rather than in ALA export.
This in vitro data was corroborated in vivo by our recent studies
showing that ABCB10 expression is essential for erythropoiesis in vivo
[38] (Fig. 2A). ABCB10 KO mice die at embryonic day 12.5 and are
severely anemic at day 10.5, when primitive erythropoiesis takes place
and heme synthesis rates are maximal in erythroid precursors (Fig. 2A)
[38]. This phenotype closely resembles GATA-1 KO mice. GATA-1 is
the master transcription factor regulating terminal erythropoiesis, as
it controls the expression of multiple transcripts essential for red
blood development (and also ABCB10 expression). Thus, GATA-1
mice are severely anemic at embryonic day 10 and die at day 11,
which is very similar to ABCB10 KO embryos phenotype [38,66,67].
In addition, GATA-1 KO erythroid differentiation is stalled beyond
the pro-erythroblast stage (when heme synthesis rates are maxi-
mal), as in ABCB10 KO [38,66,67]. Together, these data demonstratethat ABCB10, a downstream target of GATA-1, is essential for red
blood cell differentiation.
This model challenged a major prediction in regard to ABCB10
function: If ABCB10 was to export a heme synthesis intermediate,
one would predict that hemoglobin synthesis would not be possible
in the absence of ABCB10, and that erythroid cells would die with no
hemoglobin in them. This was not the case. Histology of ABCB10 KO
embryonic yolk sac and cytology of embryonic blood (day 10.5)
showed the presence of a minor population of hemoglobinized
erythroid precursors (10% of erythroid precursors had hemoglobin
and some of them were apoptotic) [38]. Therefore, there should be
mitochondrial export of heme and amino-levulinic acid in the ab-
sence of ABCB10, as hemoglobin synthesis is still possible.
How could ABCB10 regulate heme synthesis while not directly
transporting an intemediate? Our initial hypothesis was by protecting
mitochondria and/or the cell from increased oxidative stress associated
with heme/iron metabolism. Indeed, this function protecting from
mitochondrial damage or oxidative stress would be conserved to a cer-
tain extent with the yeast, fungus and C. elegans orthologs of ABCB10,
as described in the previous section (Section 2.1) [17,30,31].
Furthermore, multiple lines of evidence demonstrate the intimate
relation between erythropoiesis, heme metabolism and oxidative
stress in mammals. One example is the mice deﬁcient in one of the
main antioxidant enzymes located in the mitochondrial matrix, su-
peroxide dismutase 2 (sod2) [25,26]. Lethally irradiated mice were
rescued by implanting hematopoietic stem cells (HSC) with deleted
sod2 expression (sod2−/−) [25,26]. Despite the rescue from lethality,
these mice had a decreased number of circulating red blood cells,
showing features of sideroblastic anemia; that is, granules with iron,
inside the red blood cells [25,26]. Interestingly, reconstitution of T,
and B, myeloid cells from HSC sod2−/− was not affected [25,26].
These data strongly demonstrated that mitochondrial antioxidant ac-
tivity was particularly important for erythrocyte differentiation and
did not affect HSC differentiation to other lineages. This was some-
how expected, as the high levels of heme synthesis required for
hemoglobinization involve a large increase in free iron import inside
the mitochondria and formation of different heme intermediates,
which can cause severe oxidative damage.
Therefore, in order to test whether mitochondrial oxidative dam-
age was contributing to defective erythropoiesis caused by ABCB10
deletion, we differentiated ABCB10−/− erythroid progenitors to red
blood cells ex vivo (from ABCB10 KO day 10.5 embryonic blood) and
in vitro (from ABCB10 KO embryonic stem cells) in the presence of
a SOD2 mimetic (MnTBAP) [38]. Treatment with the catalytic antioxi-
dant MnTBAP partially restored hemoglobin synthesis and partially
prevented apoptosis after differentiation of ABCB10−/− cells to erythro-
cytes. Furthermore, a mainly cytosolic ROS scavenger (less efﬁcient in
the mitochondria), N-acetyl-cysteine, was completely unable to pre-
vent these defects [38]. These results demonstrated that ABCB10 ac-
tivity is required to avoid oxidative damage, particularly associated
with mitochondrial superoxide production during heme synthesis
and erythrocyte differentiation. However, this rescue by MnTBAP
was partial, which could be explained by three different scenarios:
1) Efﬁciency of the antioxidant treatment: possibly themaximal capac-
ity of theMnTBAP as an antioxidant was not sufﬁcient to completely
prevent the increase in oxidative stress associated with the lack of
ABCB10 and erythrocyte differentiation.
2) ABCB10was playing an additional role in erythrocyte differentiation
not directly associated to protection from oxidative damage. Indeed,
it is still possible that ABCB10 transported essential heme synthesis
intermediates (such as ALA or heme per se) when hemoglobin syn-
thesis rates are high, whereas other transporters would be responsi-
ble for ALA or heme export at lower or basal synthesis rates. These
additional transporters could explain hemoglobin synthesis in ery-
throid cells without ABCB10 expression.
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Fig. 2. ABCB10 is essential for erythropoiesis in vivo. A) Light microscope image of day
10.5 embryos still attached to the placenta and inside the yolk sac. The 2 embryos in
the upper part of the image harbor inactivated ABCB10 alleles (−/−) and showed
beating hearts. The embryo in the bottom part of the image was a wild type. Note
that the wild type embryo has hemoglobinized cells in the vasculature of the yolk sac
(giving red color to vessels), whereas the ABCB10−/− embryos show vessels with no
red color (lack of hemoglobinized cells). The yolk sac is the main site of primitive
erythropoiesis at day 9.5–10.5. See Ref. [38], Hyde, Liesa et al. (2012) Cell Death and
Differentiation for a more detailed description. B) Representative images of differenti-
ated MEL cells (murine erythroleukemia cells) stably transfected with an empty vector
(control) or containing ABCB10 cDNA (ABCB10 over-expression) and stained with benzi-
dine for hemoglobin detection (orange/brown color). This ﬁgure panel was adapted from
[76], Shirihai et al. (2000) EMBO Journal.
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dismutation of superoxide could be still leading to cell death. It will
be of interest to increase both superoxide dismutase and catalase ac-
tivities and study whether this treatment could completely rescue
defective erythropoeisis caused by ABCB10 deletion. In this regard,
if an antioxidant treatment completely rescuing hemoglobinization
in ABCB10−/− cells was identiﬁed, it would be a strong proof that
ABCB10would not be involved in the export of essential heme inter-
mediates (ALA) or heme per se when synthesis rates increase.
Different studies show that ABCB10 plays additional roles in regulat-
ing heme synthesis. In vitro data demonstrated that ABCB10 is required
to stabilize mitoferrin 1 (Mfrn1) protein levels speciﬁcally during ery-
throid differentiation of murine erythro-leukemia cell line (MEL cells)
[16]. Overexpression of ABCB10 in COS7 (non-erythroid cells) and
undifferentiated MEL cells also stabilized Mfrn1 expression [16]. There-
fore, ABCB10 has an additional indirect function regulating heme synthe-
sis, by allowing maximal iron import to the mitochondria through
Mfrn1 stabilization. Indeed, Ferrochelatase was also found in the same
complex with over-expressed ABCB10 and over-expressed Mfrn1 [15].
Whether the formation of this complex is required to stabilize
Ferrochelatase or for Ferrochelatase function is unknown [15]. Given
that Ferrochelatase was also found to interact with ABCB7, it would be
interesting to determine the exact composition of these ABCB10 com-
plexes in vivo and whether they are physiologically relevant [15,80].
Regarding the interaction between ABCB10/Mfrn1, we conﬁrmed the
likely existence of this regulatory pathway in vivo, as day 10.5embryonic blood from ABCB10 KO show a speciﬁc reduction in Mfrn1
protein levels (larger than in other mitochondrial proteins) [38].
On the other hand, different observations suggest that the interac-
tion between ABCB10 and Mfrn1 is not essential for hemoglobinization
or for the independent function of both proteins. The ﬁrst evidence is
that hemoglobinization can occur in the absence of ABCB10, demon-
strating that Mfrn1 is still active [38]. Furthermore, treatment with
antioxidant molecules increased hemoglobinization in ABCB10 KO
cells, demonstrating that Mfrn1 activity can be increased in the absence
of ABCB10 [38]. Given that iron can cause oxidative stress, it is likely that
ABCB10-mediated modulation of the mitochondrial oxidative status
could be an important signal determining Mfrn1 protein levels. Thus,
it is possible that ABCB10 could regulate Mfrn1 levels independently
of their physical presence in the same complex. Reduction in iron im-
port under conditions of increased ROS (associatedwith ABCB10 reduc-
tion)may function tomaintain cell viability andmitochondrial function
during erythroid differentiation. In this regard, it would make physio-
logical sense that if ABCB10 protective activity was impaired, the mito-
chondriawould notmaintain a high iron import activity throughMfrn1,
thereby avoiding the possibility of exacerbating mitochondrial oxida-
tive damage through iron. It would be of interest to determinewhether
Mfrn1 levels are also decreased in other models of increasedmitochon-
drial oxidative stress.
3.2.2. ABCB10 (ABC-me) in the heart
Mitochondria play a major role in heart physiology and disease
[52]. The heart has high ATP demand and mitochondria are essential
to support continuous cardiac contraction by maintaining the ATP
pool [52]. A sudden increase in mitochondrial oxidative stress is a
central mediator of cardiac damage and cell death under pathological
conditions, such as in ischemia–reperfusion (caused by a temporal
obstruction in the coronary artery, followed by re-perfusion and
re-oxygenation of the tissue) [52]. We rationalized that this would
be a relevant system in which we could study the role of ABCB10 in
protecting from oxidative stress outside the context of erythropoiesis
and hemoglobin synthesis. Indeed, heme synthesis by the mitochon-
dria supports both cytochrome synthesis as well as providing sub-
strate for the heme–oxygenase antioxidant system. [49,50]. In this
regard, cytosolic heme–oxygenase 1 is required to protect the heart
from ischemia–reperfusion [54]. Consistent with this hypothesis, the
heart shows considerable expression levels of ABCB10 [76].
Thus, we used mice harboring one functional allele of ABCB10
(ABC-me+/−), as the KO (−/−) was embryonic lethal (see previous
section). Hearts from ABCB10+/− showed a 50% reduction in ABCB10
expression. However, this reduction did not impair heart function
under resting conditions. Systolic (contraction) and diastolic (relaxa-
tion) pressure values were normal both in vivo and ex vivo, even
under different working loads using Langendorff perfusions. Consistent
with this, mitochondrial function was not impaired in isolated mito-
chondria from ABCB10+/− hearts or in intact cardiomyocytes under
basal conditions [53]. Furthermore, ABCB10+/− hearts did not show
signs of increased oxidative damage to proteins and production of su-
peroxide in isolated mitochondria was unchanged [53]. This was also
in agreement with the ﬁnding that catalase and/or Sod2 expression
were not increased in ABCB10+/− hearts, suggesting that the lack of
oxidative damage or cardiac dysfunction was not due to up-regulation
in the expression of the main antioxidant defense mechanisms. Of
note, Mfrn1 protein levels were not altered in ABCB10+/− hearts,
suggesting that reduction in ABCB10 expression levels is not associated
with decreased Mfrn1 in the heart under resting conditions [53]. Thus,
it was of interest to test how ABCB10+/− hearts would respond to
conditions of increased mitochondrial oxidative stress.
We subjected wild type and ABCB10+/− hearts to 10 min of ische-
mia and20 min of reperfusion. Tenminutes of ischemia results in bioen-
ergetic and mechanical impairment that are linked to oxidative stress
without promoting massive cell death. After ischemia–reperfusion,
1951M. Liesa et al. / Biochimica et Biophysica Acta 1823 (2012) 1945–1957ABCB10+/− diastolic function was severely impaired, together with
a milder systolic dysfunction (Fig. 3A). In parallel, ATP synthesis and
oxygen consumption rates were decreased in mitochondria from
ABCB10+/− hearts after ischemia–reperfusion, when compared to
wild type hearts. Consistent with these data, total ATP levels were
decreased by 50% in ABCB10+/− hearts when compared to wild type
hearts after ischemia–reperfusion, explaining their speciﬁc mechanical
dysfunction. Acute treatmentwith a superoxide dismutase and catalase
mimetic (EUK-207) (20 min of perfusion), prior to ischemia–reperfusion,
completely prevented both the bioenergetic and mechanical defects
caused by inactivation of one allele of ABCB10 (Fig. 3). This result
demonstrated that decreased protection from oxidative stress in
ABCB10+/− hearts was causing the exacerbated cardiac dysfunction
after ischemia–reperfusion [53].
Further experiments were carried out to investigate the site of oxi-
dative damage in the ABCB10+/− hearts. ABCB10+/− cardiacmitochon-
dria displayed a larger increase in lipid peroxidation after ischemia–
reperfusion when compared to wild type hearts [53]. Outside the
mitochondria, we found that the sarcoplasmic reticulum calcium
ATPase (SERCA), required for proper diastolic function (as it is respon-
sible for the calcium uptake from the cytosol to the endoplasmic reticu-
lum, which allows heart relaxation), was sulfonylated in cysteine 674
[53]. This oxidative post-translational modiﬁcation in cysteine 674 is
known to inactivate SERCA function. Therefore, in addition to
decreased mitochondrial ATP synthesis, SERCA inactivation likely
contributed to diastolic dysfunction [53]. Both mitochondrial lipid
peroxidation and SERCA sulfonylation induced by ABCB10 partial inac-
tivationwere completely prevented by the treatmentwith the superox-
ide dismutase/catalase mimetic EUK-207 [53]. Interestingly, a similar
EUK compound was used to prevent some of the hematopoietic defects
associated with Sod2 inactivation [25,26]. These results suggested that
an increase in superoxide/hydrogen peroxide levels in ABCB10+/−
mitochondria could be causing this phenotype of poor recovery after
ischemia–reperfusion. In addition, diffusion of hydrogen peroxide
from the mitochondria could be responsible for SERCA inactivation.
This study demonstrated that ABCB10 protective function is con-
served in non-hematopoetic tissues (tissues without hemoglobin syn-
thesis or without very high heme synthesis rates). Furthermore, these
in vivo models are compatible with the hypothesis formulated in the
previous section by which lack of MDL1/ABCB10 could be causing oxi-
dative damage (and in the case that ABCB10 harbors export activity):
1. Causing the accumulation of its substrate in the mitochondrial ma-
trix, leading to dysfunction and ROS generation (through higher
order structures and/or reaching toxic concentrations).
2. Lack of a signal exported from the mitochondria required to acti-
vate an antioxidant response and/or mitochondrial quality control
mechanisms to counteract ROS-mediated damage.
In the following section we will summarize the function of the rest
of mitochondrial ABC transporters. All three have been also implicat-
ed in oxidative stress handling to some extent but the mechanisms
are likely to be different from ABCB10.
4. Understanding ABCB10 function by phylogenetic
comparison: Mitochondrial members of the ABCB
family and conserved functions
ABC transporters are the preferred agents of transport in bacteria.
Close to 5% of E. coli K12 genome is constituted by genes encoding for
components of ABC (ATP binding cassette) transporters, resulting in
78 different proteins with the ABC signature [37]. This relatively
high percentage in E. coli suggests that ABC-mediated transport (im-
port or export) could constitute one of the main molecular mecha-
nisms selected during evolution for adaptation and communication
of unicellular organisms with the environment (i.e. nutrient uptake,
and excretion of toxic metabolic end-products).However, this high requirement for ABC transporters in bacteria is
not present in other unicellular organisms that share similar ecologi-
cal niches. This suggests that the requirement of ABC proteins in
E. coli is not related to the direct interaction of the unicellular organ-
ism with the ecological niche. For example, a eukaryotic unicellular
organism such as S. cerevisae expresses 29 ABC proteins (3 times less
than E. coli). Of these 29 ABC proteins, 72% are class 1 (with fused
inter-membrane and ABC domains) and none are class 3 (the inter-
membrane and ABC domains are carried by independent poly-peptide
chains) [37]. This distribution of ABC proteins is exactly the opposite
of the prokaryote E. coli K12, which expresses only a 9% of class 1 ABC
proteins and an 81% of class 3 [37]. This proﬁle in S. cerevisae
suggested that the majority of class 3 ABC proteins are not required
for unicellular life. In all, one could conclude that ABC transport function
is a preferred mechanism to constitute a fully functional prokaryotic
organism, whichwould have a relative lower importance in eukaryotes.
On the other hand, the α-proteobacteria R. prowazekii only ex-
presses 14 ABC proteins (6 class 1 and 6 class 3) [37]. This suggests
that most of these class 3 ABC proteins expressed in E. coli are not
required to constitute a functional prokaryotic unit. This low require-
ment for ABC transporters could be partially explained by the parasitic
nature of R. prowazekii and thus, the more protected environment
that confers living inside the host cell. Therefore, these 14 proteins in
R. prowazekiimight be the essential ABC proteins permitting basic pro-
karyotic physiological processes. Studying the functional conservation
in eukaryotes andmammals of these 14ABC proteins fromR. prowazekii
will provide very valuable information. It will be important to deter-
mine whether ABCB10 function is conserved between eukaryotic and
prokaryotic cells, as mitochondria are thought to be developed through
endosymbiosis of the α-proteobacteria R. prowazekii [4]. Consequently,
the understanding of ABC proteins conferring the parasitic properties
and/or allowing basic physiological processes of Rickettsia can poten-
tially unravel molecular mechanisms of interaction between the mito-
chondria and the rest of the cell.
There are only 3 additional ABC proteins located in the mitochon-
dria of mammalian cells and all of them are class 1 (as ABCB10):
ABCB6, ABCB7 and ABCB8 [37]. BLAST protein sequence homology
analysis shows that human ABCB6 and ABCB7 show high and similar
levels of identity to R. prowazekii ABC protein ATM1 (57% identity,
covering 98% of the human ABCB6 protein sequence and 49% identity,
covering 79% in the case of ABCB7). In the case of human ABCB10 and
ABCB8, the closest R. prowazekii ABC protein is Multi-drug resistance
protein, but their similarity is lower (31% of identity, covering only
67% of ABCB10 sequence and 32% of identity, covering 71% of ABCB8
sequence). These data are consistent with phylogenic analysis of the
mitochondrial ABC transporters, in which human ABCB6, ABCB7 and
S. cerevisae ATM1 cluster together, whereas ABCB10 and ABCB8 clus-
ter separately [30,88,89] (see Fig. 4). Of note, ABCB10 clusters togeth-
er with yeast MDL1 (multidrug resistance like 1), whereas ABCB8 is in
a separate cluster from ABCB10 and MDL1 [30,88,89].
Altogether, these ﬁndings suggest that ABCB8 and ABCB10 might
play a more specialized eukaryotic function similar to yeast MDL1 or
to Rickettsia multidrug resistance protein, whereas ABCB6 and ABCB7
might play a more conserved function related to ATM1 that is likely
common to prokaryotes and eukaryotes.
4.1. ABCB6/MTABC3
ABCB6 is located in the outer mitochondrial membrane and was
shown to be involved in the import of porphyrins, including heme,
coproporphyrinogen III, and protoporphoryrinogen IX inside the mi-
tochondria, as its ATP binding domain is facing the cytosol [47,65].
However, the inner membrane protoporphoryrinogen IX importer
has not been identiﬁed yet. Therefore, it was suggested that ABCB6
was essential for erythropoiesis, as coordinated protoporphyrinogen
IX import through the outer and inner membrane is a step required
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Fig. 3. ABCB10 is required to protect from increased oxidative stress associated to cardiac ischemia–reperfusion. A) Diastolic and systolic pressure in wild type (WT) and ABCB10+/−
hearts (red trace) during ischemia–reperfusion. Increased diastolic and decreased systolic pressures are symptomatic of impaired mechanical function. Pre-treatment for 20 min
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erythroid cells [47].
These ﬁndings could be consistent with a highly conserved function
of ABCB6 through evolution (and thus its high degree of identitywith its
prokaryotic ortholog), as heme is synthesized in R. prowazekii to support
their aerobic metabolism. Indeed, according to KEGG pathway analysis
and other BLAST studies [63,64], R. prowazekii does not express the
prokaryotic ortholog of uroporphyrinogen III synthase (named hemD),
which would abrogate its ability to synthesize protoporphyrinogen IX
[64]. Therefore, R. prowazekii would require the import of porphyrins
from the host cell to complete heme synthesis and compensate the
lack of hemD (only in that case that there is deﬁnitive proof that other
unidentiﬁed enzyme with Uroporphyrinogen III synthase activity and
completely unrelated to prokaryotic hemD did not exist). Furthermore,
ABCB6 show ubiquitous expression, which is consistent with the fact
that all cell types require heme synthesis to different extents [47,58].
In this regard, some studies demonstrated that ABCB6 expression was
protective against different insults increasing oxidative stress, such as
arsenite exposure [12,55]. The mechanism for this protection is that
heme is required to assemble catalase in the peroxisome [22,49,50].
On the other hand, different lines of evidence suggest that ABCB6
might play other roles not directly related to heme synthesis and
protoporphoryrinogen IX import in the mitochondria, such as provid-
ing multi-drug resistance activity to cancer cell lines [27,68,86]. In
this regard, several studies have shown that ABCB6 is also located in
the plasmamembrane, ER and Golgi apparatus (as part of the secreto-
ry pathway) [41,43,65,82,85]. It was also shown that certain muta-
tions in ABCB6 might cause an ocular disease named coloboma in
humans [85]. In this study, ABCB6 was also detected in the ER andGolgi of retinal pigment epithelial cells, consistent with other studies
showing that ABCB6 is not exclusively mitochondrial [85]. In addition,
two recent reports challenged directly the physiological relevance of
ABCB6 activity importing porphyrins, its mitochondrial localization
and thus its role in hemoglobin synthesis [32,46]. The ﬁrst study
showed that ABCB6 is dispensable for erythropoiesis and hemoglobin
synthesis [32]. Human subjects harboring mutations abrogating
ABCB6 protein expression did not present any defect in erythropoiesis,
hemoglobin synthesis or anemia [32]. They only presented a mild in-
crease of intracellular porphyrin levels in circulating red blood cells
and a decrease in the porphyrin plasma levels [32]. In addition, ABCB6
was detected in the plasma membrane of red blood cells [32,43].
These results suggest that ABCB6 located in the plasma membrane
might be mediating the export of porphyrin from red blood cells to
the serum. The second study demonstrates that ABCB6 is not located
to the mitochondria and is not required for heme biosynthesis in dif-
ferentiating K562 human erythroid cells. As a result, this study con-
cludes that ABCB6 should not be considered as a mitochondrial ABC
transporter [46].
It could also be possible that ABCB6 played an indirect role in
protoporphyrinogen IX mitochondrial import, by stabilizing and/or
activating the unidentiﬁed porphyrin importer in the inner membrane
(or others present in the outer membrane). It would be important to
reconstitute puriﬁed ABCB6 in proteoliposomes, which would allow
testing whether ABCB6 in isolation is sufﬁcient to import porphyrins
or requires the presence of other proteins. This technique would also
facilitate the identiﬁcation of additional potential substrates and thus
the understanding of ABCB6 function not directly related to heme me-
tabolism. In all, these data suggest that ABCB6 harbors specialized
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Fig. 4.Mitochondrial ABC transporters cluster according to their different physiological roles reported. A) Phylogenic analysis: dendogram obtained using ClustalW2 software from
the EMBL website and using the aminoacid sequences of ABC proteins. Hs: Homo sapiens; Sc: Saccharomyces cerevisae (fungi); Rp22: Rickettsia prowazekii strain 22 (prokaryote,
ancestor of mitochondria); Pb: Paracoccidioides brasiliensis (fungi). Note that human ABCB7 clusters together with ATM1 from S. cerevisae and from R. prowazekii, suggesting
that its function permitting iron/sulfur cluster synthesis is likely to be conserved. ABCB6, despite its high levels of aminoacid identity by BLAST protein analysis to ABCB7 and
ATM1Sc, clusters separately. This separation ﬁts well with ABCB6 heterogeneous localization inside the cell and the likely possibility that it transports multiple substrates.
ABCB10, Pfr1 and MDL1 have all been shown to be required for protection under conditions of increased oxidative stress related to heme and iron metabolism. Consistent with
this, they cluster together. ABCB8, on the other hand, has been reported to be involved in different processes, such as multidrug resistance in cancer cell lines (in doxorubicin
export), mitochondrial K+ ATP channel, iron and GSH export in the heart. These heterogeneous functions suggest a less conserved and more specialized function of ABCB8. In ad-
dition, MDR (multidrug resistance protein) of R. prowazekii clusters separately from ABCB10 and ABCB8. R. prowazekii MDR function is unknown, but we think that it will be closer
to ABCB10, as the latter clusters together with lower eukaryotes orthologs, suggesting a more conserved function. B) Sequence alignment of human ABCB10 (ABCB10Hs) with
S. cerevisae MDL1 (Mdl1pSc) and P. brasiliensis Pfr-1 (Pfr1Pb) using Clustal W2 software. Identical residues are marked with asterisks. The transmembrane-TM- and nucleotide
binding-NBD-domains, according to ABCB10 sequence, are in light green and grey respectively. TheWalker A, B and C-loop motifs are highlighted within the NBD in different colors.
ABCB10 mitochondrial target sequence (MTS) is also highlighted in orange. Note that MTS is the less conserved region of the protein.
1953M. Liesa et al. / Biochimica et Biophysica Acta 1823 (2012) 1945–1957function/s in eukaryotic cells that might not be shared with its
R. prowazekii ortholog.
4.2. ATM1 and ABCB7 (ABC7)
ATM1 (ATP binding cassette TransporterMitochondria 1) was iden-
tiﬁed in yeast and its discovery constituted the ﬁrst description of a
mitochondrial ABC transporter [51]. ATM1 is located in the inner mito-
chondrial membrane, with the ATP binding domain facing the matrix
(therefore it should export molecules to the inter-membrane space)
and functions as a homodimer [18,51]. Although the molecular entity/
ies transported by yeast ATM1 or by its mammalian ortholog ABCB7
have not been identiﬁed, their function is known [18,19,73,75]: they
both regulate iron/sulfur cluster assembly and iron homeostasis (and
heme in the case of ABCB7, through interaction with ferrochelatase)
[44,45,69,74,80]. In this regard, deletion of ATM1 or ABCB7 causesmito-
chondrial iron accumulation, oxidative damage to themitochondria and
cytosolic iron starvation, together with defective assembly of cytosolic
iron/sulfur clusters [44,45,69,70]. This highly conserved function
and mitochondrial sub-localization suggests that ABCB7 mightconserve, to some extent, the function of its R. prowazekii ortholog (de-
spite showing a lower % of identity when compared to ABCB6). Indeed,
R. prowazekii lacks important proteins regulating iron transport and
regulation [64]. Thus, it could be possible that the host cell was respon-
sible for the handling of free iron, while R. prowazekii would export
intermediates to the host cell cytosol through ATM1, free iron would
be incorporated to this exported intermediate in the host cell and the
ﬁnalmolecule containing iron (i.e. iron/sulfur cluster)would be imported
back into R. prowazekii. By avoiding handling free iron, the parasite
R. prowazekiiwouldhave lower internal exposure to free iron toxicity, uti-
lizing the host cell protectivemechanisms and intermediate biosynthesis.
On the other hand, this hypothesis would not be consistent with
the fact that the formation of mitochondrial iron/sulfur clusters does
not require cytosolic steps in mammalian cells (in other words, the for-
mation of iron/sulfur cluster in themitochondria is not compartmental-
ized between mitochondria and cytosol). However, it could be possible
that during the endosymbiotic evolution, the host cell transferred these
functions to mitochondria (no longer parasitic, when compared to
R. prowazekii), thereby to further minimize the toxic effects of free
iron in the rest of the cell.
1954 M. Liesa et al. / Biochimica et Biophysica Acta 1823 (2012) 1945–1957Consistent with ABCB7 function described in vitro, studies using
mouse models abrogating ABCB7 activity showed that ABCB7 is es-
sential for iron/sulfur cluster biogenesis and hematopoeisis in vivo
[69,70]. Mutations in ABCB7 cause X-linked sideroblastic anemia
with spinocerebellar ataxia (X-LSA/A) in humans and mouse models
[1,9,56,72,75]. The sideroblastic anemia is caused by iron accumula-
tion inside mitochondria of erythroid cells in the patients, together
with defects in hememetabolism and iron sulfur cluster protein assem-
bly. Therefore, the molecular mechanism of this disease is explained by
an alteration in iron homeostasis. The cause for spinocerebellar ataxia
in these patients is not known yet. This effect in non-hematopoietic
tissues is consistent with ABCB7 expression among different cell types
[73]. Thus, understanding the function of ABCB7 in brain, among other
tissues, will be relevant to understand the development of the ataxia
in XLSA/A patients. In this regard, the absence of ABCB7 did not cause
lethality in the liver despite affecting iron/sulfur cluster formation,
suggesting that the importance of ABCB7 function is different depending
on the cellular type [69]. The identiﬁcation of ABCB7 substrate/s will
provide valuable information in order to understand not only ABCB7
function in iron metabolism, but also the speciﬁc relevance of ABCB7
activity in each tissue. Structure studies will be important to validate
and conﬁrm the candidate molecules (whether they ﬁt the substrate
binding site).4.3. ABCB8 (M-ABC1/mABC1)
ABCB8 is expressed in 23 human tissues (data not shown by
Hogue et al. [36]), suggesting a ubiquitous presence and function
in different tissues. Evidence gathered so far does not link this
transporter to heme biosynthesis, which is consistent with its rel-
atively higher degree of homology to multi-drug resistance like pro-
teins (MDL1 in yeast or Multidrug resistance protein in R. prowazekii)
when compared to ATM1. The main function attributed to yeast MDL1
is the export of peptides produced from inner membrane proteins deg-
radation [87]. However, ABCB8 homology toMDL1 is lower when com-
pared to ABCB10 (MDL1 and ABCB10 cluster together in phylogenetic
analysis, ABCB8 separately) [88,89], which suggests that ABCB8 might
play different roles than MDL1. Indeed, studies suggest that ABCB8
(M-ABC1/mABC1) constitutes the mitochondrial KATP channel and its
over-expression protects from H2O2 induced cell death in neonatal rat
cardiomyocytes [5,6]. This protective effect from oxidative stress could
be explained by the cardioprotective role of mitochondrial KATP channel
activity. In addition, different studies show that both ABCB8 and
ABCB10 are part of the human breast and colorectal “cancer genomes”
[77] and that ABCB8 is up-regulated in leukemic cells resistant to the
anti-cancer drug doxorubicin [28]. Of note, knock-down of ABCB10 by
siRNA did not decrease the resistance of melanoma cells to doxorubicin
[24]. In marked contrast, down-regulation of ABCB8 using siRNA signif-
icantly reversed resistance of melanoma cells to the toxic effects of
doxorubicin [24]. In addition, ABCB8 down-regulation resulted in in-
creased doxorubicin-mediated damage to the mitochondrial DNA [24].
Importantly, doxorubicinwas also found to accumulate inside themito-
chondria of cell lines [2]. Therefore, it is possible that ABCB8 participates
in the export of doxorubicin from the mitochondria, a function that
would not be sharedwith ABCB10. Indeed, it was recently demonstrated
that cardiac ABCB8 is speciﬁcally required to protect from the cardiotoxic
effects of doxorubicin [40]. Furthermore, additional evidence shows
that ABCB8 regulates mitochondrial export of GSH and iron in cardiac
cells, which could also explain an additional role protecting from oxida-
tive stress, independently of its attributed‐to KATP channel activity
[5,8,39]. It will be valuable to deﬁne the exact substrates of ABCB8 in
order to understand the precise molecular mechanism by which
ABCB8 regulates the transport of K+, iron, GSH and doxorubicin. This va-
riety of potential ABCB8 substrates is consistent with its homology to
multi-drug resistance like proteins, as they are able to transport a varietyof different molecular entities (i.e. MDR1 is ABCB1, a member of the
same family that ABCB8).
In order to determine ABCB8 substrate/s, experiments involving the
puriﬁcation of ABCB8 and reconstitution in proteoliposomes are re-
quired. These experiments will allow determining whether ABCB8 per
se (in isolation) is able to transport K+, iron, GSH (reduced glutathione)
and doxorubicin or whether it requires the presence of other proteins.
These studies will provide deﬁnitive evidence on whether different
candidate molecules can bind to and be transported by ABCB8.
4.4. Multi-drug resistance activity vs. heme/iron regulation
The 3 members of mitochondrial ABC transporters described in the
previous section share different characteristics: the ﬁrst one is that
they are widely expressed across different tissues. This would suggest
that they are regulating a physiological process relevant for most cell
types (such as MDR activity or heme/iron metabolism). The second
one is that they function as homodimers, and not as heterodimers. In
principle, lack of heterodimer formation would suggest completely in-
dependent and sufﬁcient functions of each protein. In this regard,
phylogenic and functional analysis show that ABCB6 and ABCB7 might
be involved in the regulation of iron and heme homeostasis (located
in different membranes and orientation, but they cluster together in a
phylogenic analysis), whereas ABCB8 function would be more related
to multidrug resistance activity and peptide export (i.e. export of mole-
cules that if they accumulate can result in mitochondrial damage and
dysfunction; it clusters separately in a phylogenetic analysis).
However, this separation (ABCB6/ABCB7 vs. ABCB8) according
to both phylogeny and main conserved functions is not completely ac-
curate, as there is evidence showing that ABCB6 can act as a multi-drug
resistance protein in some cancers, whereas ABCB8might regulate iron
export from the mitochondria [8,27,39,68,89]. The most important
evidence is that yeast MDL1 (ABCB10 ortholog and ABCB8 to a lesser
extent) is able to partially restore mitochondrial respiratory capacity
impaired by ATM1 (ABCB7 and ABCB6 ortholog) deletion in yeast, by
reducing 50% the increase in mitochondrial iron content (and thus
protecting from mitochondrial oxidative stress)[17]. Unexpectedly,
MDL1 overexpression in a wild type background causes higher sensitiv-
ity to oxidative stress (in the same direction as ATM1 deletion, therefore
the opposite than expected), without dramatically affecting iron homeo-
stasis [17]. Thus, although it was expected that ABCB7 and ABCB6 would
be the only mitochondrial ABC proteins regulating the oxidative status
(indirectly because of their role regulating heme/iron metabolism),
MDL1 and ABCB8 (the multi-drug resistance like proteins) can also regu-
late it. However, the main difference between MDL1 and ABCB8 is that
ABCB8 overexpression can protect against oxidative stress (H2O2 expo-
sure) in a wild type background, whereas MDL1 overexpression does ex-
actly the opposite (sensitizes to H2O2 exposure). This paradoxical
behavior suggests thatMDL1 functionwould beprotecting fromoxidative
stress only under speciﬁc conditions (such as ATM1 deletion). Thus, un-
derstanding ABCB10 (MDL1 closest mammalian ortholog) function can
help to determine: a) the intimate functional relationship betweenmito-
chondrial multi-drug resistance activity, heme/iron metabolism and pro-
tection from oxidative stress, b) unraveling a potential novel target to
treat pathologies involving abnormally increasedmitochondrial oxidative
stress, c) the physiology behind this paradoxical role of MDL1 in the con-
text of yeast metabolism d) the functional relationship (if any) between
ABCB6, ABCB7 and ABCB8.
5. Conclusions and perspectives
Recent evidence demonstrated that ABCB10 plays a protective role
against increased oxidative stress in hematopoietic tissues and in the
heart. The precise mechanisms are still unknown, but they are likely to
be different from the rest of mitochondrial ABC transporters (ABCB6,
ABCB7 andABCB8). In this regard, themolecularmechanismsdescribing
1955M. Liesa et al. / Biochimica et Biophysica Acta 1823 (2012) 1945–1957the function of these 3 transporters (ABCB6, ABCB7 and ABCB8) are also
still unknown, but the physiological consequences of their modulation
have been described, revealing important differences from ABCB10
function. In the case of ABCB6, recent evidence demonstrated that its
function is not essential for erythropoiesis and that abrogation of its
expression does not cause any major symptoms in humans. Thus,
ABCB6 might be playing a yet uncharacterized role in addition to por-
phyrin transport modulation. ABCB8 function is not completely under-
stood. ABCB8 was suggested to be part of the mitochondrial KATP
channel and to protect from oxidative stress in cardiac cells. In addition,
recent evidencedemonstrated that ABCB8 regulates iron andGSHexport
from the mitochondria, in addition to protecting from doxorubicin-
induced mitochondrial damage in heart. Therefore, it is likely that
ABCB8 indirectly modulates the oxidative status of the cell by several
as yet uncharacterized multi-drug resistance-like mechanisms, which
involve K+, iron and GSH transport. ABCB7 mutations cause X-linked
sideroblastic anemia with ataxia in humans, as a consequence of altered
iron/sulfur cluster formation, to which erythroid cells are particularly
sensitive. The exact mechanism by which ABCB7 regulates iron/sulfur
cluster biogenesis is unknown, but it is likely that it exports an essential
intermediate for cytosolic iron/sulfur cluster formation. This activity
regulating heme/ironmetabolism explains ABCB7 activity regulating ox-
idative status. Therefore, understanding the precise mechanism by
which ABCB7 regulates iron/sulfur cluster formation will provide very
valuable information towards the cure of XLSA. However, this is not an
easy task, as different research groups have tried for a long time to iden-
tify ABCB7/ATM1 substrate without success.
ABCB10 is the only mitochondrial ABC transporter described to pro-
tect from increased oxidative stress associated with heme metabolism
in higher eukaryotes, rather than being essential for heme synthesis or
the formation of iron/sulfur clusters per se. This hypothesis is supported
by the fact that some ABCB10−/− erythroid cells are hemoglobinized
and that this hemoglobinization is partially restored by antioxidant
treatments. We expect that mutations/inactivation of ABCB10 might
be contributing to congenital and/or drug-induced anemias related to
increased mitochondrial oxidative stress in humans. Furthermore, we
expect that ABCB10 inactivation will cause defects in other human tis-
sues, particularly the ones sensitive tomitochondrial oxidative stress as-
sociated to hememetabolism, such as the heart, liver, brain and kidney.
Thus, ABCB10 might be an interesting candidate to explain the adverse
effect of some drugs in red blood cells formation (anemia) and in de-
creased recovery of cardiac function after ischemia–reperfusion. In this
regard, the future identiﬁcation of ABCB10 substrate/s will facilitate
the determination of drugs competing/inhibiting ABCB10 function by
comparing their structures. Importantly, it will also determine whether
ABCB10 activation (and/or preventing its inhibition) could be potential-
ly used to efﬁciently protect from conditions causing increased mito-
chondrial oxidative stress, such as ageing, anemia, cardiac ischemia–
reperfusion or neurodegenerative diseases.
In all, the description of this novel mechanism protectingmitochon-
dria from oxidative stress deﬁned by ABCB10 could constitute an im-
portant step forward to understand and treat pathologies associated
with increased mitochondrial oxidative stress.
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